All company sites gemabank.ru celltranspl.ru reprobank.ru genetico.ru stem-cells.ru sprs-therapy.ru celltech.ru neovasculgen.ru Russian English About company Press Center Directions Products Investors 23.09 HSCI to talk about gene-assisted bone regeneration at the Annual Congress of the European Association of Cranio-Maxillofacial Surgeons From 23 to 26 September, Prague will host the XXII Congress of the EACMFS (European Association of Craniomaxillofacial Surgeons), at which specialists from the Human Stem Cell Institute (HSCI) will present a report "Gene-activated bone grafts: challenges and opportunities", which was based on experimental results of bone tissue restoration with the help of gene technologies obtained at HSCI. 18.09 The scientific journal published by HSCI will be published under the new name "Genes and Cells" HSCI announces the renaming of the scientific journal Cellular Transplantology and Tissue Engineering (KTTI). The Federal Service for Supervision in the Sphere of Communications and Information Technologies and Mass Communications has registered the magazine under the new name "Genes and Cells" All news Human Stem Cell Institute (HSCI) The Human Stem Cell Institute (HSCI) is a Russian public biotechnology company founded in 2003. HSCI's areas of activity are the development, commercialization, and marketing of its own innovative medicines and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. The company aims to create a new culture of medical care for a person - the development of healthcare in the field of personalized and preventive medicine. HSCI owns the country's largest bank for personal storage of cord blood stem cells - Gemabank , as well as the bank of human reproductive cells - Reprobank (personal storage and donation). The company brought to the market the first Russian gene therapy drug for the treatment of lower limb ischemia of atherosclerotic genesis - Neovasculgen ® , as well as an innovative medical technology for the use of dermal autofibroblasts to restore skin with signs of age-related and other structural changes - SPRS-therapy . HSCI is implementing a socially significant project to create a nationwide network of Genetico medical genetic centers to provide genetic diagnostics and counseling services for the early detection and prevention of hereditary diseases, as well as pathologies with a genetic component ( Ethnogen , PGD , Prenetix , etc.). The company aims to develop its products in the Russian and world markets. OJSC HSCI is the issuer of the RII sector of the Moscow Exchange (ticker: ISKJ ). HSCI's initial public offering in December 2009 was the first IPO of a biotech company in Russia. Disclaimer List of insider information © 2003-2014 Human Stem Cell Institute